Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytosorbents Corp - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
CTSO
Nasdaq
3845
https://cytosorbents.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytosorbents Corp
CTSO: CytoSorbents reports 3rd quarter 2023 financial and operating results which showed strong product revenue growth and an improved cost structure.
- Nov 14th, 2023 1:10 pm
Q3 2023 Cytosorbents Corp Earnings Call
- Nov 10th, 2023 2:42 pm
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 1:52 pm
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
- Nov 9th, 2023 9:15 pm
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
- Oct 27th, 2023 11:00 am
CytoSorbents to Present at the 8th Annual Dawson James Conference
- Oct 5th, 2023 11:00 am
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
- Sep 27th, 2023 11:00 am
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
- Sep 19th, 2023 11:00 am
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
- Sep 11th, 2023 3:32 pm
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
- Sep 1st, 2023 8:43 pm
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
- Aug 31st, 2023 11:00 am
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 83% loss from investing in the stock five years ago
- Aug 27th, 2023 1:52 pm
CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial
- Aug 14th, 2023 11:00 am
CTSO: CytoSorbents reports 2nd quarter 2023 financial and results which showed strong product revenue growth and an improved cost structure.
- Aug 3rd, 2023 1:10 pm
Q2 2023 Cytosorbents Corp Earnings Call
- Aug 2nd, 2023 1:02 pm
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
- Aug 1st, 2023 8:15 pm
Several Insiders Invested In Cytosorbents Flagging Positive News
- Jul 31st, 2023 11:31 am
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
- Jul 26th, 2023 11:00 am
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
- Jul 19th, 2023 11:00 am
Scroll